ECYT News Alert Endocyte Inc (ECYT) 5.26 02/14/2015 09:22:30

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 10:22 AM

Endocyte Inc (ECYT) 5.26 $ECYT

Critical Alerts For Transocean, Crane, Achillion Pharmaceuticals, Endocyte and Monster Beverage Released By InvestorsObserver
PR Newswire - Wed Feb 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for RIG, CR, ACHN, ECYT and MNST.
MNST: 117.74 (-1.77), ECYT: 5.26 (-0.02), RIG: 19.05 (+0.42), ACHN: 10.89 (-0.20), CR: 68.19 (-0.40)

Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)

Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Jan 30, 3:00PM CST

BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), PCYC: 163.28 (+0.23), ZSPH: 46.77 (+3.42), RMTI: 11.17 (+0.15), BCLI: 3.86 (-0.02), SIEN: 15.90 (+0.38), JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), SNY: 49.42 (+0.82), LENS: 6.00 (-0.67), REGN: 402.40 (+0.66), SYK: 94.51 (+1.14), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), AMGN: 153.48 (+0.30), APPY: 0.45 (-0.01), MNKD: 7.00 (+0.02), CELG: 115.88 (+0.16), ISRG: 510.73 (+3.02), GILD: 101.90 (+1.10), ANIP: 62.69 (-0.43), MRK: 58.81 (-0.07), ALXN: 182.29 (+6.02), CCXI: 7.85 (+0.04), ICPT: 209.12 (+7.12), AEZS: 0.53 (unch), ATRS: 2.45 (+0.05), NASH: 31.48 (+0.01)

Endocyte, Small Company, Small Valuation, Full Pipeline
Doug Van Cuyk - at Seeking Alpha - Fri Jan 30, 12:22PM CST

ECYT: 5.26 (-0.02)

Critical Alerts For Transocean, Endocyte, American Airlines, Goldman Sachs and Netflix Released By InvestorsObserver
PR Newswire - Mon Jan 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for RIG, ECYT, AAL, GS and NFLX.
NFLX: 466.10 (+9.37), ECYT: 5.26 (-0.02), GS: 189.00 (-0.78), RIG: 19.05 (+0.42), AAL: 48.39 (+0.51)

Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST

ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 4:42PM CST

ECYT: 5.26 (-0.02), ECR: 7.29 (+0.12), RNET: 36.40 (+2.22), OSGB: 5.14 (+0.04), MDU: 21.57 (+0.02), REXX: 5.08 (+0.13), GTI: 4.16 (+0.32), EPE: 12.90 (+0.56), CDE: 7.27 (+0.07), AREX: 8.15 (+0.27)

OTC Daily Alert Stock Watch - Endocyte (Nasdaq: ECYT)
WorldStockWire - Mon Dec 29, 2:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ECYT: 5.26 (-0.02)

Others Overlooked Endocyte (ECYT), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:46AM CST
A company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Endocyte (ECYT)
ECYT: 5.26 (-0.02)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)

Why Endocyte (ECYT) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:43AM CST
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ECYT’s earnings for the coming quarter and year.
ECYT: 5.26 (-0.02)

Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance
PR Newswire - Wed Nov 26, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ:VVUS), Horizon Pharma PLC (NASDAQ: HZNP), Endocyte Inc. (NASDAQ: ECYT), Johnson and Johnson (NYSE: JNJ), and Theravance Inc. (NASDAQ: THRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 25, 2014, the NASDAQ Composite ended at 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 17,814.94, and the S&P 500 closed at 2,067.03, down 0.12%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 0.07%, with the index also advancing 8.30% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 99.62 (+1.18), ECYT: 5.26 (-0.02), HZNP: 16.84 (-0.41), VVUS: 2.68 (+0.13), THRX: 14.85 (+1.00)

Can Endocyte (ECYT) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 7:46AM CST
Endocyte has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat.
ECYT: 5.26 (-0.02)

Nasdaq stocks posting largest percentage increases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SWIR: 37.45 (+0.12), PERI: 3.24 (unch), UNXL: 5.12 (-0.19), TREE: 42.92 (+0.40), SSRI: 6.26 (+0.13), STMP: 56.92 (-0.24), RPRX: 8.76 (+0.09), NYNY: 6.33 (+0.06), SHLD: 35.70 (+2.32), AREX: 8.15 (+0.27), PGNX: 5.66 (+0.06), ECYT: 5.26 (-0.02), SSO.TO: 7.81 (+0.16), SGMA: 6.61 (-0.10), SW.TO: 46.63 (+0.05), PLNR: 6.63 (-0.07)

Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 5.26 (-0.02), AUXL: 36.47 (-0.06), ADHD: 6.92 (+0.73), BIOD: 1.38 (-0.14)

Endocyte's (ECYT) CEO Ron Ellis on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:52PM CST

ECYT: 5.26 (-0.02)

Endocyte beats 3Q profit forecasts
Automated Insights - Wed Nov 05, 6:27PM CST
WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a third-quarter loss of $5.7 million.
ECYT: 5.26 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...